Stay updated on Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial page.

Latest updates to the Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange Detected- Updated the page to include a government-operating-status notice and a new version tag (v3.2.0), replacing the old v3.1.0.SummaryDifference4%

- Check30 days agoChange DetectedUpdate: version bumped to v3.1.0 and new contact details added (oncosohn@yuhs.ac) with a corresponding informational identifier; previous version v3.0.2 is removed.SummaryDifference0.1%

- Check44 days agoChange DetectedUpdated page revision from v3.0.1 to v3.0.2 and removed the 'Back to Top' link. No other core content or critical data changed.SummaryDifference0.2%

- Check51 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.2%

- Check59 days agoChange DetectedThe web page has updated its facility name and location details, specifically emphasizing Seoul, South Korea, and the inclusion of 'Skin and Connective Tissue Diseases' and 'pembrolizumab' as key topics.SummaryDifference2%

- Check73 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial page.